Clinical trials · Minnesota
Renal Cell Carcinoma (Kidney Cancer) clinical trials in Minnesota
We’re tracking 18 recruiting renal cell carcinoma (kidney cancer) studies with a site in Minnesota — including Phase 1, Phase 1/Phase 2, Phase 2, Phase 2/Phase 3 and Phase 3 studies, each written for real people, not researchers.
Recruiting studies in Minnesota
- NCT06661720RecruitingPhase 3
Tivozanib and pembrolizumab after kidney cancer surgery
This trial is testing if adding the targeted therapy tivozanib to the immunotherapy drug pembrolizumab (Keytruda) can help prevent kidney cancer from coming back after all known tumors have been removed by surgery.
Bemidji, MinnesotaAges 18 years+ - NCT05334069Recruiting
Blood test study for early cancer detection in patients
This study collects blood from people with cancer and people without cancer (or with possible cancer) to test whether new blood tests can detect cancer earlier. Your blood samples help researchers evaluate how well these tests work.
Aitkin, MinnesotaAges 40–75 - NCT03866382RecruitingPhase 2
Immunotherapy plus a targeted drug for rare genitourinary tumors
This Phase 2 study tests whether nivolumab and ipilimumab (immunotherapy drugs) plus cabozantinib (a targeted anti-cancer drug) can shrink or control rare cancers of the urinary/reproductive system that have spread. It may help by boosting the immune system and blocking cancer growth signals at the same time.
Aitkin, MinnesotaAges 18 years+ - NCT07227402RecruitingPhase 3
Study of belzutifan and zanzalintinib for recurrent kidney cancer
This trial tests two new drugs, belzutifan and zanzalintinib, for people with advanced kidney cancer that returned after or within 2 years of finishing an immunotherapy treatment after surgery. You cannot have received any other cancer treatments besides that immunotherapy.
Saint Louis Park, MinnesotaAges 18 years+ - NCT04510597RecruitingPhase 3
Immunotherapy plus surgery versus immunotherapy alone for kidney cancer
This study tests whether adding surgery to remove the kidney improves outcomes compared with continuing immunotherapy without surgery. It is for people with metastatic kidney cancer whose disease has not worsened after initial immunotherapy.
Cambridge, MinnesotaAges 18 years+ - NCT04981119Recruiting
Test apheresis for CAR T manufacturing in HLA-A2 solid tumors
This trial studies how a process called apheresis is used to make CAR T cells for people with certain solid tumors. It is designed for tumors that have lost a specific immune marker (HLA-A*02), which may affect how well CAR T therapies work.
Rochester, MinnesotaAges 18 years+ - NCT05327686RecruitingPhase 2
Adding focused radiation to immunotherapy for kidney cancer
This Phase 2 trial studies whether adding focused, high-precision radiation to immunotherapy helps people with advanced kidney cancer (that cannot be removed by surgery or has spread). It aims to improve cancer control by combining two treatment approaches.
Bemidji, MinnesotaAges 18 years+ - NCT06026410RecruitingPhase 1
KO-2806 for advanced solid tumors
This trial tests a new drug called KO-2806, alone or with other treatments, for people with advanced solid tumors that have specific gene changes (like HRAS or KRAS mutations). It may help if standard treatments have stopped working.
Rochester, MinnesotaAges 18 years+ - NCT06349642Recruiting
Testing a live tumor test for immune therapy response
This trial uses a special test on live tumor samples to see if it can predict how well immune checkpoint inhibitors (a type of immunotherapy) will work for different cancers. It may help doctors choose the best treatment for you.
Rochester, MinnesotaAges 18 years+ - NCT06682793RecruitingPhase 1/Phase 2
Study of A2B395 therapy for solid tumors with EGFR and HLA loss
This trial tests a new cell therapy called A2B395 for cancers that have EGFR, a protein on the cell surface, and have lost a specific marker called HLA-A*02. The therapy uses specially engineered immune cells to target and kill these cancer cells. This may help patients with colorectal, lung, head and neck, breast, kidney, or other solid tumors that are no longer responding to standard treatments.
Rochester, MinnesotaAges 18 years+ - NCT06693336RecruitingPhase 2
Adjuvant chemotherapy trial for early-stage lung cancer
This trial tests a chemotherapy drug called SMS001 (a form of paclitaxel) after surgery for non-small cell lung cancer. It may help prevent the cancer from coming back.
Rochester, MinnesotaAges 18–80 - NCT07510334RecruitingPhase 2
VSV Virus Plus Immunotherapy for Advanced Kidney Cancer
This trial tests a combination of a special virus (VSV-IFNβ-NIS) with two immunotherapy drugs (ipilimumab and nivolumab) for people with advanced clear cell kidney cancer that hasn't been treated yet. It aims to see if this approach helps shrink tumors or slow the disease.
Rochester, MinnesotaAges 18 years+ - NCT06885424Enrolling by invitation
Long-term follow-up for A2 Bio gene therapy patients
This study follows up with people who previously received a gene therapy product from A2 Biotherapeutics in an earlier trial. The goal is to monitor their health over time and check for any long-term effects.
Rochester, MinnesotaAges 18 years+ - NCT05987241RecruitingPhase 2/Phase 3
Using a blood test to guide immunotherapy after bladder/kidney cancer surgery
This study tests whether a blood test that detects tumor DNA can help guide the use of immunotherapy (nivolumab with or without relatlimab) after surgery for urothelial cancer. The goal is to see if starting immunotherapy based on the blood test results can prevent the cancer from coming back.
Bemidji, MinnesotaAges 18 years+ - NCT07097142RecruitingPhase 3
Shorter radiation for bladder cancer with chemo
This trial tests if a shorter course of radiation therapy works as well as the usual longer course for people with bladder cancer who are also receiving standard chemotherapy. The goal is to see if shorter treatment can reduce side effects while still being effective.
Burnsville, MinnesotaAges 18 years+ - NCT06552169RecruitingPhase 2
Treg cell therapy to lower anti-rejection meds after kidney transplant
This trial tests whether adding a special type of immune cell (Treg cells) to standard therapy can help kidney transplant recipients safely take lower doses of anti-rejection medicines. It is for people who are getting a kidney from a living donor.
Rochester, MinnesotaAges 18–65 - NCT06712654RecruitingPhase 2
Testing AP306 for high phosphate in dialysis patients
This trial tests a new medication called AP306 for people on hemodialysis who have high blood phosphate. It aims to see if the drug is safe, tolerable, and helps lower phosphate levels.
Edina, MinnesotaAges 18 years+ - NCT06668493RecruitingPhase 1/Phase 2
A virus-based treatment for low-grade upper tract bladder cancer
This trial tests a new drug, nadofaragene firadenovec, which uses a harmless virus to deliver a signal that helps your immune system fight low-grade cancer in the upper part of the urinary tract (the kidney area). It's given directly into the kidney through a small tube, and may avoid more invasive surgery.
Rochester, MinnesotaAges 18 years+
Where these studies are running in Minnesota
Institutions with a site for the recruiting renal cell carcinoma (kidney cancer) studies listed above.
- Mayo Clinic · 11 studies
- Abbott-Northwestern Hospital · 7 studies
- Fairview Southdale Hospital · 7 studies
- Hennepin County Medical Center · 7 studies
- Regions Hospital · 7 studies
- Mercy Hospital · 6 studies
- Park Nicollet Clinic - Saint Louis Park · 6 studies
- Saint Francis Regional Medical Center · 6 studies
What taking part in a renal cell carcinoma (kidney cancer) study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Renal Cell Carcinoma (Kidney Cancer) trials in other states
Common questions
- Are there renal cell carcinoma (kidney cancer) clinical trials in Minnesota?
- Yes. We're currently tracking 18 recruiting renal cell carcinoma (kidney cancer) studies with a site in Minnesota, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a renal cell carcinoma (kidney cancer) study in Minnesota?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in Minnesota to take part?
- Not necessarily. These studies have a site in Minnesota, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a renal cell carcinoma (kidney cancer) trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New renal cell carcinoma (kidney cancer) studies open in Minnesota regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.